Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ) · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium leads to lower number of patients with a clinically significant worsening (≥ 4… compared with placebo (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium leads to lower number of patients with one or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in number of patients with one or more exacerbations requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Hospital admissions · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in number of patients with one or more hospitalisations for any cause compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with COPD who have smoked for ≥ 10 pack‐years
Tiotropium showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review